37 results about "Lung cancer early detection" patented technology

An electronic nose system for early detection of lung cancer comprises an exhaled air sampling system, a miniature sensor array and a signal preprocessing and pattern recognizing system, wherein the exhaled air sampling system is used for controlling air collection, circulation and rinsing; the miniature sensor array is used for collecting air response signals and converting the air response signals into electrical signals; the signal preprocessing and pattern recognizing system is used for signal processing, conversion and air identification and detection; the exhaled air sampling system comprises an air sampling device and an air chamber air passage unit; the miniature sensor array is encapsulated in the sensor air chamber of the air chamber air passage unit; and the signal preprocessing and pattern recognizing system is arranged outside the sensor air chamber and is connected with the miniature sensor array. The electronic nose system has the advantages of high sensitivity, high response speed, low cost, portability, and easiness in operation; a data base has excellent expandability; and the electronic nose system can be widely applied to early detection of lung cancer, monitoring after recovery and screening of high-risk populations.

The invention provides a mass spectrum model for detecting characteristic proteins of a lung cancer. The mass spectrum model comprises peaks with mass charge ratios of 4054 m/z, 2273 m/z, 4091 m/z, 3955 m/z, 3192 m/z, 3884 m/z and 5337 m/z, wherein in the model, proteins expressing the mass charge ratios of 4054 m/z, 2273 m/z, 4091 m/z, 3955 m/z, 3192 m/z, 3884 m/z and 5337 m/z are serum characteristic proteins of the lung cancer; and when the peaks with the mass charge ratios of 4054 m/z, 2273 m/z, 4091 m/z, 3955 m/z and 3192 m/z are expressed in a down regulation manner and the peaks with the mass charge ratios of 3884 m/z and 5337 m/z are expressed in an up regulation manner, a patient is indicated to be a lung cancer patient or a potential patient. The mass spectrum model can be used for early detection and screening for the lung cancer; the method is simple, easy to operate and high in accuracy; and by utilizing the mass spectrum model, a novel idea is provided for early detection and screening for the lung cancer.

The invention relates to a methylation marker for early detection of cancer and a detection method thereof. The methylation marker comprises PCDHGB6, HOXA9, MGMT and microRNA-126 genes. The methylation marker has the advantages of quickness, high throughput, high sensitivity and high specificity when being adopted for combined detection, and the detection method is suitable for early detection of cancer, can be used for late detection of lung cancer and has a good application prospect.

The invention relates to the field of biological detection, particularly to a group of microRNA biological markers for early lung cancer diagnosis and an application thereof. The microRNA biological marker comprises hsa-miR-125a-5p, hsa-miR-193a-5p, hsa-miR-25, hsa-miR-126 and hsa-miR-34a. The serum miRNA biological markers comprising the 5 miRNAs can not only be particularly applied to early lung cancer detection, but also be applied to advanced lung cancer detection.

The invention relates to an exosome ecDNA biomarker detection reagent for the early diagnosis of lung cancer. The biomarker comprises exosome ecDNA biomarkers C-myc, EGFR and CyclinD1, and is used asa biomarker for predicting early lung cancer. The invention provides and verifies that the advantages of rapidness, no harm, high accuracy and high specificity are achieved when the exosome ecDNA is used as a biomarker expression level for the early diagnosis of lung cancer for the first time, and thereby the detection reagent has important significance for the early diagnosis of lung cancer.

The invention discloses a prediction model for early diagnosis of lung cancer as well as related products and application of the prediction model. The prediction model comprises the following factors: age, gender, arginine, aspartic acid, serine, glutaryl carnitine, isovaleryl carnitine and eicocarbonyl carnitine. The invention further provides a system and a device based on the prediction model and a computer readable storage medium, the early-stage rapid and effective prediction of the lung cancer can be realized, and the method has a very excellent application prospect.

The invention discloses application of a GASP-2 detection reagent in preparation of a kit for early diagnosis and susceptibility detection of lung cancer, and belongs to the field of cancer diagnosis. In serum of a lung cancer patient, the content of GASP-2 is obviously higher than that of normal people. According to the early diagnosis kit for the lung cancer, the lung cancer can be rapidly and accurately diagnosed by detecting the content of GASP-2, and the early diagnosis rate of the lung cancer can be increased, so that the prognosis of a patient with the lung cancer is greatly improved, and the disease burden of the lung cancer is reduced.

The invention discloses a group of peripheral blood circulation microRNAs related to diagnosis and treatment of lung cancer and application of the peripheral blood circulation microRNAs. The microRNA is prepared from the following components: hsa-miR-16-5p, hsa-miR-26a-5p, hsa-miR-15b-5p, hsa-miR-21-5p, hsa-miR-191-5p, hsa-miR-195-5p, hsa-miR-223-3p, hsa-miR-92a-3p, hsa-let-7a-5p, hsa-let-7f-5p, hsa-miR-451a and hsa-miR-150-5p. The microRNA specific detection primer and the application of the microRNA specific detection primer in the kit are firstly protected; and a product has a function of diagnosis or auxiliary diagnosis of lung cancer. In addition to protecting a specific primer sequence, a reverse transcription primer, a specific upstream primer and a universal downstream primer are further included; and the microRNA is obviously up-regulated in peripheral blood of the lung cancer, has the advantages of good stability, high specificity and high sensitivity, can be independently used or a combination of more than two microRNAs to assist clinical early diagnosis or prognosis monitoring of the lung cancer, and has important application value.

The invention discloses application of an SDPR gene expression level detection reagent and/or an SDPR gene methylation level detection reagent in preparation of a kit used for diagnosing whether a subject suffers from lung cancer or not, or used for predicting whether the subject has a lung cancer risk or not, or used for judging whether a lung cancer patient is sensitive to chemotherapeutic drugsor not, or used for judging whether the lung cancer patient has good prognosis or not, and belongs to the field of molecular diagnosis. The invention provides a new clinical marker for early diagnosis and treatment of lung cancer, and has huge clinical value.

The invention discloses application of ASPH gene in an exosome in a lung cancer early diagnosis kit, and belongs to the technical field of gene detecting. The invention discloses the application of the ASPH gene in the exosome in the lung cancer early diagnosis kit. The kit comprises a primer for detecting the ASPH gene in the exosome and a primer for detecting beta-actin. The application of the ASPH gene in the exosome in the lung cancer early diagnosis kit disclosed by the invention is high in detecting sensitivity and strong in specificity.

The present invention relates to a marker for early diagnosis and distant metastasis prediction of lung cancer based on platelet LncRNA-STON2 and a prepared kit thereof, and belongs to the fields of medical treatment and public health. The marker is selected from the plasma platelet LncRNA-STON2. The kit prepared from the marker comprises a reverse transcription reaction system, a fluorescence quantitative PCR reaction system and an internal reference system. The present invention also provides a preparation method of the kit. The marker is firstly provided. Compared with healthy donors, an expression level of the LncRNA-STON2 in the plasma platelets of patients with the lung cancer is significantly increased, and a ROC curve analysis shows that AUC is 0.613, sensitivity is 61.5%, and specificity is 59.9%. Compared with the healthy donors, the expression level of the LncRNA-STON2 in patients with early lung cancer is significantly increased, and the ROC curve analysis shows that the AUC is 0.713, the sensitivity is 69.2% and the specificity is 71.9%.

The invention provides an application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as a combined diagnosis marker in early diagnosis of a lung cancer, and belongs to the technical field of medical diagnosis. A condition thata TIF1 gamma protein is abnormally highly expressed in cancer tissues of a patient with an early lung cancer is found for the first time; meanwhile, a strong humoral immune response aiming at TIF1gamma is found to exist in a body of the patient at the early stage of the lung cancer; serum anti-TIF1 gamma-IgA and TIF1 gamma-IgG autoantibodies can be used as markers for early diagnosis of the lung cancer; and combined detection of the anti-TIF1 gamma-IgA and the anti-TIF1 gamma-IgG can obviously improve sensitivity of the early diagnosis of the lung cancer patient on the basis of ensuring specificity, and the application is suitable for being developed into a combined detection kit with a clinical application value. Therefore, the combined detection of the anti-TIF1gamma-IgA and the anti-TIF1 gamma-IgG is helpful for further improving early serological screening quality of the lung cancer patient so that a cure rate and a five-year survival rate of the lung cancer are increased.

The invention discloses a sample data intelligent processing method and system for early lung cancer diagnosis, and the method comprises the steps: building a diagnosis sample database through obtaining experimental data requirements; obtaining a first experiment parameter; based on the first experiment parameter, obtaining a first experiment data set through a diagnosis sample database; obtaining a first function relationship according to the first experimental data set; sequentially inputting the first experimental data set into the first function relationship to obtain a first calculation result; obtaining a first data cost function according to the first calculation result and the first experimental data set; obtaining a first coefficient according to the first data cost function; substituting a first coefficient into the first function relation to obtain a first parameter diagnosis relation; and obtaining a first parameter diagnosis result according to the first experimental parameter and the first parameter diagnosis relationship. The technical problems that in the prior art, lung cancer early diagnosis sample data is complex, the reliability of the sample data affects the reliability of an experimental result, and the experimental effect is reduced are solved.